Trump announces trade deal with EU following months of negotiations
Aptorum Group Ltd (NASDAQ:APM), a pharmaceutical company, disclosed today that it has received a notice from the Nasdaq Stock Market regarding a non-compliance issue with the minimum bid price requirement. According to a report filed with the Securities and Exchange Commission (SEC), the notification indicated that the company’s shares had been trading below the required minimum bid price of $1.00 for a period of 30 consecutive business days.
The SEC filing, dated Wednesday, outlines the Nasdaq’s listing rule that mandates a company’s stock must maintain a minimum average closing bid price of $1.00 over a consecutive 30 trading-day period. Aptorum Group, which is incorporated under the name 03 Life Sciences and headquartered in London, United Kingdom (TADAWUL:4280), is now subject to a 180-day grace period to regain compliance with the Nasdaq’s minimum bid price requirement. InvestingPro analysis indicates the company faces challenges with a significant debt burden and rapid cash burn rate, though analysts expect sales growth in the current year.
During this 180-day period, which ends on October 13, 2025, Aptorum Group must see its common stock’s closing bid price reach or exceed $1.00 for at least ten consecutive business days to meet the Nasdaq’s standard. If the company fails to achieve compliance within the allotted timeframe, it may be eligible for an additional 180-day grace period, provided it meets all other listing standards and requirements for an initial listing on the Nasdaq Capital Market, except for the bid price. Despite recent challenges, InvestingPro data shows the stock has demonstrated strength with a 46% return over the past week, though it remains down 86% over the past year. Get access to 13 additional ProTips and comprehensive analysis with an InvestingPro subscription.
The company’s CEO, Ian Huen, signed the SEC report, affirming the accuracy of the information provided. This notice does not result in the immediate delisting of Aptorum Group’s common stock, and the shares will continue to trade on the Nasdaq under the ticker symbol APM. The company has yet to announce its plans to address the deficiency but will be required to monitor its bid price and consider available options to resolve the issue. With the next earnings report due on April 25, investors can access detailed financial analysis and Fair Value estimates through InvestingPro’s comprehensive research reports, available for over 1,400 US stocks.
Aptorum Group focuses on the development of pharmaceutical preparations, as indicated by its Standard Industrial Classification (SIC) code. The notice is a routine communication regarding listing standards, and receiving such a notification is not uncommon for companies whose stock prices fluctuate below the set threshold. The information presented is based on the press release statement filed with the SEC.
In other recent news, Andean Precious Metals reported record revenues of $254 million in Q4 2024, with a net income of $19.2 million, or $0.12 per share. The company also achieved a record adjusted EBITDA of $62.9 million, despite facing challenges such as a temporary suspension of operations at Golden Queen. Looking ahead, Andean Precious Metals has set a 2025 production guidance of between 102,900 and 117,200 gold equivalent ounces. Meanwhile, Aptorum Group received a notice of non-compliance from Nasdaq due to its share price falling below the required minimum bid price of $1. The company has until October 14, 2025, to address this issue, with potential actions including a reverse stock split to maintain its Nasdaq listing. Aptorum Group remains focused on its efforts in developing treatments for diseases with unmet medical needs. Analysts and investors will be watching closely as the company navigates these challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.